Press release from Companies

Publicerat: 2021-12-17 08:00:00

DanCann Pharma A/S: DanCann Pharma A/S: CEO, Jeppe Krog Rasmussen (Xignotus Capital ApS), locks his position in DanCann Pharma for 3 years - and thereby more than 21% of the total share capital

COPENHAGEN, Denmark, 17 December 2021 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, hereby announce that the CEO of DanCann Pharma, Jeppe Krog Rasmussen (indirectly through his holding company: Xignotus Capital ApS ("Jeppe Krog Rasmussen" or "Xignotus Capital")), has chosen to lock his position in talks with the Board of Directors of DanCann Pharma in an Agreement (the "Agreement") which locks Jeppe Krog Rasmussen's position in the company for another 36 months, under the Agreement and agreed Conditions (the "Conditions"), with effect from 1 January 2022 up to and including 31 December 2024 (the "Period"), which today consists of 5,667,023 shares, which constitutes to approx. 21.34% of the total share capital at a fair value as of today (before market open 17 December 2021) of 27,768,412.7 DKK (share price: 4.900).

Motive for the Agreement and Conditions:

  • Aggressive CEO lock-up mechanism
  • Show full commitment from Founder, Board Member, CEO and major shareholder
  • Step beyond traditional lock-up mechanism

CEO, Jeppe Krog Rasmussen, comments:

"Looking just a few years back to when and where it all started, it’s truly amazing what we have accomplished, building up this company from scratch. It has continuously required a lot of dedication, long nights, and sacrifice – and I’m still standing with an even stronger belief in being able to make a difference for the many patients, who need a company like ours.

This is my little child that I have given birth to with my very first own money and capital back in the days, seen it become a teenager and soon to become an adult, something I do not want to miss.

I do this to show my fully commitment and dedication to this project, and because I believe in an even brighter future with some truly amazing milestones in front of us."

The Agreement and the Conditions

The Agreement and the Conditions is subject to Jeppe Krog Rasmussen retaining his positions in the Company as CEO and Board Member, unless any other agreement is reached, and thus subject to this being terminated upon complete takeover of the Company (complete acquisition of DanCann Pharma, or more than 51% of the total share capital).

Under the Conditions, Jeppe Krog Rasmussen is in his position to sell under certain Conditions, but only to a very limited extent based on certain milestones to be reached (please see table below). It is very important to emphasize, that Jeppe Krog Rasmussen, and hereby Xignotus Capital, has no intention of selling parts of his shareholding. However, it is an opportunity formally written into the Agreement which can only be activated if certain ambitious milestones are reached cf. the Agreement and the Conditions.

2021 2022** 2023** 2024** 2025
Starting point (17 December 2021): 4.900 DKK (Company value: 130.1 MDKK) Sales of 10% if the market cap is above: 250 MDKK* Sales of 10% if the market cap is above: 400 MDKK* Sales of 10% if the market cap is above: 650 MDKK* New agreement to be reached.
Number of shares in Jeppe Krog Rasmussen depot as of today (16 December 2021): 5,667,023 shares Equal maximum: 566,702 shares Equal maximum: 566,702 shares Equal maximum: 566,702 shares Minimum number of shares in Jeppe Krog Rasmussen depot after 2024: 3,966,917 shares

* Based on a volume-weighted average price ("VWAP") for the 30 consecutive trading days preceding to any sales.
** The 10% from each year will be applicable going forward (total 566,702x3 = 1,700,106 shares over the three-year period).


Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology.

Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities.

Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this presentation are made as of the date of this presentation and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

About DanCann Pharma

DanCann Pharma A/S (SS: DANCAN) was founded in 2018 and is a Danish biopharmaceutical Company powered by cannabinoids. DanCann Pharma is a vertically integrated, licensed production and distribution Company based in Denmark. The Company focuses on discovering, developing, manufacturing, and commercializing new therapeutic cannabinoids in a wide range of disease areas.

DanCann Pharma A/S (SS: DANCAN) is listed on the Spotlight Stock Market in Copenhagen.
For more information, visit:

For further information, please contact:

Jeppe Krog Rasmussen, CEO

Läs mer hos Cision
Läs mer om DanCann Pharma A/S